Production & Sales - Marketing & Sales

Y.S.P. Industries to market TaiGen’s new drug in Malaysia and Singapore

Y.S.P. Industries has entered into an exclusive licensing agreement to develop and market TaiGen Biopharmaceuticals Holdings’ (TaiGen) new drug in Malaysia and Singapore.

Lupin acquires five brands and associated trademark rights from Menarini

Indian pharmaceutical firm Lupin has entered into an agreement to acquire five brands along with associated trademark rights from the units of Menarini -- A. Menarini India Private Limited and A. Menarini Asia-Pacific Holdings.

TheracosBio’s commercialises type 2 diabetes oral tablet

TheracosBio has announced the commercial availability of Brenzavvy (bexagliflozin) oral tablet for the treatment of adults with type 2 diabetes by prescription through the Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs).

Astellas Pharma completes acquisition of Iveric Bio

Astellas Pharma, through its indirect wholly owned subsidiary, Berry Merger Sub, has completed the acquisition of Iveric Bio.

Alvotech partners with Advanz for biosimilars commercialisation in Europe

Alvotech and Advanz Pharma have extended their strategic partnership for the supply and commercialisation of five biosimilars in Europe.

Navamedic announces $7.2m cash offer for Sensidose acquisition

Nordic pharma company Navamedic ASA has offered $7.2m (SEK75m) to purchase all shares in Sweden-based pharmaceutical firm Sensidose AB.

OncoVent signs agreement with Orient EuroPharma for oregovomab

Shenzhen Hepalink Pharmaceutical Group’s subsidiary OncoVent has entered into a licence and distribution agreement with Orient EuroPharma (OEP) for the immunotherapeutic drug candidate, oregovomab.

Adaptimmune and Genentech partner on allogeneic cell therapies

Adaptimmune Therapeutics has signed a strategic partnership and licence agreement with Roche Group member, Genentech, for the development and commercialisation of allogeneic cell therapies across several cancer indications.

SciNeuro and Eli Lilly sign exclusive license agreement for alpha-synuclein in Greater China

Biopharmaceutical company SciNeuro Pharmaceuticals has signed an exclusive license agreement with Eli Lilly and Company for the development and commercialisation of alpha-synuclein targeted antibody therapies in Greater China.